Granted Patent
B2
US 12,351,877 · App. 17/253,690 · Granted Jul 8, 2025
Systems and methods for determining a treatment course of action
C12Q1/6886A61K31/015A61K31/10A61K31/138A61K31/4196A61K45/06G01N33/57484C12Q2600/106C12Q2600/158G01N2333/723
View Patent ↗
Loading inventors, assignments & file history…
Abstract
The present disclosure relates to methods of determining a treatment course of action. In particular, the present disclosure relates to compositions and methods for determining responsiveness to estrogen and estrogen blocking therapies for cancer.
Claims (12)
1. A method of treating breast cancer in a subject, comprising:
a) assaying a sample comprising breast cancer cells from a subject diagnosed with breast cancer for the level of expression of Enah/Vasp-Like gene (EVL);
b) assaying said sample for the level of expression of estrogen receptor;
c) identifying said breast cancer cells as having a level of expression of EVL lower than a reference level, wherein said reference level is the level of EVL in estrogen receptor negative breast cancer cells;
d) identifying said breast cancer cells as estrogen receptor positive; and
e) administering anti-estrogen adjuvant therapy to the subject identified as having estrogen receptor positive breast cancer cells and a level of expression of EVL lower than said reference level.
2. The method of claim 1 , wherein said anti-estrogen therapy is an estrogen receptor antagonist or an aromatase inhibitor.
3. The method of claim 1 , wherein said anti-estrogen therapy is selected from the group consisting of tamoxifen, fulvestrant, toremifene, letrozole, anastrozole, and exemestane.
4. The method of claim 1 , wherein said method further comprises administering chemotherapy.
5. The method of claim 1 , wherein following administration of said anti-estrogen therapy, estrogen therapy is administered to said subject.
6. The method of claim 5 , wherein said subject does not exhibit a response to said anti-estrogen therapy.
7. The method of claim 5 , wherein said estrogen therapy promotes the generation of Suppressive Cortical Actin Bundles (SCABs).
Assignments (2)
ASSIGNMENT OF ASSIGNOR'S INTEREST
Recorded May 16, 2022
From: MOUNEIMNE, GHASSAN; PADILLA-RODRIGUEZ, MARCO
To: ARIZONA BOARD OF REGENTS ON BEHALF OF THE UNIVERSITY OF ARIZONA
Reel/Frame 059918/0777 →
CONFIRMATORY LICENSE
Recorded Jan 6, 2021
From: UNIVERSITY OF ARIZONA
To: NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT
Reel/Frame 054906/0250 →
Continuity (2)
Provisional Application
62688156
· Jun 21, 2018
References Cited (81)
US 5225326A
· Bresser et al.
· 1993
[cited by applicant]
US 5545524A
· Trent
· 1996
[cited by applicant]
US 6121489A
· Dorner et al.
· 2000
[cited by applicant]
US 6573043B1
· Cohen et al.
· 2003
[cited by applicant]
US 6690976B2
· Fenn et al.
· 2004
[cited by applicant]
US 8658396B2
· Turner et al.
· 2014
[cited by applicant]
US 20080193938A1
· Kun
· 2008
[cited by examiner]
WO WO2009100161
· 2009
[cited by applicant]
WO WO2011019074
· 2011
[cited by applicant]
NCBI Gene entry for EVL, available from https://www.ncbi.nlm.nih.gov/gene/51466, updated Oct. 15, 2023, printed as pp. 1/8-8/8; e.g., p. 1. (Year: 2023).
[cited by examiner]
Hormone Therapy for Breast Cancer, published by the National Cancer Institute. Available from https://www.cancer.gov/types/breast/breast-hormone-therapy-fact-sheet on Jan. 20, 2017, printed as p. 1/4-4/4. (Year: 2017).
[cited by examiner]
Jordan et al. New hypotheses and opportunities in endocrine therapy: amplification of oestrogen-induced apoptosis. The Breast, vol. 18, vol. S3, pp. S10-S17, 2009. (Year: 2009).
[cited by examiner]
Jordan, VC. The 38th David A. Karnofsky Lecture: The Paradoxical Actions of Estrogen in Breast Cancer—Survival or Death? Journal of Clinical Oncology, vol. 26, pp. 3073-3082, Jun. 20, 2008. (Year: 2008).
[cited by examiner]
Kai et al. Force matters: Biomechanical regulation of cell invasion and migration in disease. Trends in Cell Biology, vol. 25, No. 7, pp. 486-497, Jul. 2016. (Year: 2016).
[cited by examiner]
Barcus et al. Dense collagen-I matrices enhance pro-tumorigenic estrogen-prolactin crosstalk in MCF-7 and T47D breast cancer cells. PLoS ONE, vol. 10, No. 1, e0116891, Jan. 21, 2015; printed as pp. 1/22-22/22. (Year: 20…
[cited by examiner]
Reinert et al. Multidisciplinary approach to neoadjuvant endocrine therapy in breast cancer: A comprehensive review. Revista brasileira de ginecologia e obstetrícia : revista da Federação Brasileira das Sociedades de Gi…
[cited by examiner]
Fischer et al. Hematoxylin and eosin staining of tissue and cell sections. CSH Protocols, vol. 3, No. 5, pp. 1-3, May 2008. (Year: 2008).
[cited by examiner]
Entry for “estrogen receptor negative” in the NCI Dictionary of Cancer Terms. https://www.cancer.gov/publications/dictionaries/cancer-terms/def/estrogen-receptor-negative, printed as p. 1/1, publicly available Feb. 6, 2…
[cited by examiner]
Hasebe et al. Fibrotic focus in invasive ductal carcinoma: An indicator of high tumor aggressiveness. Japanese Journal of Cancer Research, vol. 87, pp. 385-394, Apr. 1996. (Year: 1996).
[cited by examiner]
Cizeron-Clairac et al. BMC Cancer (2015) 15:499, pp. 1-14.
[cited by examiner]
Bastarrachea et al., Annals of Internal Medicine, 120: 18 [1994].
[cited by applicant]
Behbod, F. et al. Breast Cancer Res. 11, R66 (2009).
[cited by applicant]
Bonnier, P. et al. International Journal of Cancer 79, 278-282 (1998).
[cited by applicant]
Branton et al., Nat. Biotechnol. 26(10):1146-53 (2008).
[cited by applicant]
Bravo-Cordero et al. Curr. Opin. Cell Biol. 24, 277-283 (2012).
[cited by applicant]
Cancer Genome Atlas Network. Nature 490, 61-70 (2012).
[cited by applicant]
Carroll, J. S. et al. Cell 122, 33-43 (2005).
[cited by applicant]
Chou, Y.-Y. et al. Identification and Characterization of a Novel Broad-Spectrum Virus Entry Inhibitor. J. Virol. 90, 4494-4510 (2016).
[cited by applicant]
Ginestier, C. et al. Clinical Cancer Research 12, 4533-4544 (2006).
[cited by applicant]
Curtis, C. et al. Nature 486, 346-352 (2012).
[cited by applicant]
Cutuli, B. et al. Breast Cancer Res Treat 95, 55-64 (2006).
[cited by applicant]
Delgado, R. C. & Lubian Lopez, D. M. Maturitas 38, 147-156 (2001).
[cited by applicant]
Drmanac, et al., Nat. Biotechnol. 16:54-58 (1998).
[cited by applicant]
Edwards et al., Journal of Clinical Oncology 16: 2693 [1998].
[cited by applicant]
Eid et al., Science 323:133-138 (2009).
[cited by applicant]
Elledge et al., Journal of the National Cancer Institute 86: 705 [1994].
[cited by applicant]
Esserman, L. J. et al. Breast Cancer Res Treat 132, 1049-1062 (2012).
[cited by applicant]
Fischer, R. S., et al., Curr. Biol. 19, 260-265 (2009).
[cited by applicant]
Gao, Y. et al. Nature Communications 8, 14483 (2017).
[cited by applicant]
Gatrell, A. C., et al. Transactions of the Institute of British Geographers 21, 256 (1996).
[cited by applicant]
Giretti et al. Rapid regulatory actions of sex steroids on cell movement through the actin cytoskeleton, Steroids, 2008, vol. 73, pp. 895-900.
[cited by applicant]
Gluck, S. et al. Breast Cancer Res Treat 132, 781-791 (2012).
[cited by applicant]
Haque, R. et al. Biomarkers Prev. 21, 1848-1855 (2012).
[cited by applicant]
Harris et al., Science 320:106-109 (2008).
[cited by applicant]
International Search Report & Written Opinion, International Patent Application No. PCT/US2019/038433, mailed Sep. 24, 2019, 13 pages.
[cited by applicant]
Kanchanawong, P. et al. Nature 468, 580-584 (2010).
[cited by applicant]
Kao, K.-J., et al. BMC Cancer 11, 143 (2011).
[cited by applicant]
Kato, Int. J. Clin. Exp. Med. 2:193-202 (2009).
[cited by applicant]
Klinger, et al., Am. J. Hum. Genet. 51:55-65 (1992).
[cited by applicant]
Korde, L. A. et al. Breast Cancer Res Treat 119, 685-699 (2010).
[cited by applicant]
Korlach et al., Proc. Natl. Acad. Sci. USA 105:1176-1181 (2008).
[cited by applicant]
Kuo, et al., Am. J. Hum. Genet. 49:112-119 (1991).
[cited by applicant]
Levene et al., Science 299:682-686 (2003).
[cited by applicant]
Lomakin, A. J. et al. Nat. Cell Biol. 17, 1435-1445 (2015).
[cited by applicant]
Lu, X. et al. Breast Cancer Res Treat 108, 191-201 (2008).
[cited by applicant]
Maclean et al., Nature Rev. Microbiol., Apr. 2009, 7: 287-296.
[cited by applicant]
Margulies et al., Nature 437:376-380 (2005).
[cited by applicant]
Maxam et al., Proc. Natl. Acad. Sci. USA 74:560-564 (1977).
[cited by applicant]
Meyer, A. S. et al. J. Cell Biol. 197, 721-729 (2012).
[cited by applicant]
Miyake, T. et al. Cancer Sci. 103, 913-920 (2012).
[cited by applicant]
Mouneimne, G. et al. Differential remodeling of actin cytoskeleton architecture by profilin isoforms leads to distinct effects on cell migration and invasion. Cancer Cell 22, 615-630 (2012).
[cited by applicant]
The BAC Resource Consortium, Integration of cytogenetic landmarks into the draft sequence of the human genome, Nature 409: 953-958 (2001).
[cited by applicant]
Obi, N. et al. International Journal of Cancer 138, 2098-2108 (2016).
[cited by applicant]
Platet, N., et al. Crit. Rev. Oncol. Hematol. 51, 55-67 (2004).
[cited by applicant]
Rauh, C. et al. Geburtshilfe Frauenheilkd 75, 588-596 (2015).
[cited by applicant]
Richardson, A. L. et al. Cancer Cell 9, 121-132 (2006).
[cited by applicant]
Ronaghi et al., Anal. Biochem. 242:84-89 (1996).
[cited by applicant]
Ruparel et al., Proc. Natl. Acad. Sci. USA 102:5932-5937 (2005).
[cited by applicant]
Sacchini, V. et al. Ann. Surg. Oncol. 9, 266-271 (2002).
[cited by applicant]
Sage, D. et al. Quantitative evaluation of software packages for single-molecule localization microscopy. Nat. Methods 12, 717-724 (2015).
[cited by applicant]
Sanger et al., Proc. Natl. Acad. Sci. USA 74:5463-5467 (1997).
[cited by applicant]
Schuetz, F. et al. American Journal of Obstetrics and Gynecology 196, 342.e1-342.e9 (2007).
[cited by applicant]
Sflomos, G. et al. A Preclinical Model for ERα-Positive Breast Cancer Points to the Epithelial Microenvironment as Determinant of Luminal Phenotype and Hormone Response. Cancer Cell 29, 407-422 (2016).
[cited by applicant]
Shtengel, G. et al. Interferometric fluorescent super-resolution microscopy resolves 3D cellular ultrastructure. Proc. Natl. Acad. Sci. U.S.A. 106, 3125-3130 (2009).
[cited by applicant]
Stickeler, E. et al. Oncol. Rep. 26, 1037-1045 (2011).
[cited by applicant]
Vicente-Manzanares et al., J. Cell Biol. 176, 573-580 (2007).
[cited by applicant]
Vidya, R. BMJ 321, 179-179 (2000).
[cited by applicant]
Voelkerding et al., Clinical Chem., 55: 641-658, 2009.
[cited by applicant]
Ward, et al., Am. J. Hum. Genet. 52:854-865 (1993).
[cited by applicant]